Works Cited

1. Brenner BM (ed). Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Elsevier; 2016.

2. Levine DZ. Caring for the Renal Patient. 3rd ed. Philadelphia, PA: Saunders; 1997.

3. Mandal AK. Hypokalemia and hyperkalemia. Med Clin North Am. 1997;81(3):611-639.

4. Jameson JL, Fauci AS, Kasper DL, Hauser S, Longo D, Loscalzo J. Harrison's Principles of Internal Medicine. 20th ed. New York, NY: McGraw-Hill; 2018.

5. Barker LR, Fiebach NH, Kern DE, et al. (eds). Principles of Ambulatory Medicine. 7th ed. Baltimore, MD: Lippincott, Williams and Wilkins; 2007.

6. MedlinePlus. Potassium Test. Available at Last accessed April 30, 2021.

7. Merck Manual. Hypokalemia. Available at Last accessed April 30, 2021.

8. Garth D. Hypokalemia in Emergency Medicine. Available at Last accessed April 30, 2021.

9. Lederer E, Alsauskas ZC, Mackelaite L, Nayak V. Hyperkalemia. Available at Last accessed April 30, 2021.

10. Castro D, Sharma S. Hypokalemia. Treasure Island, FL: StatPearls Publishing; 2021.

11. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551.

12. Abbas S, Ihle P, Harder S, Schubert I. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. Pharmacoepidemiol Drug Saf. 2015;24(4):406-413.

13. Vardeny O, Claggett B, Anand I, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7(4):573-579.

14. Desai AS, Liu J, Pfeffer MA, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018;24(5):313-320.

15. Greenberg A. Primer on Kidney Diseases. 5th ed. Philadelphia, PA: Saunders; 2009.

16. Velickovic-Radovanovic RM, Mitic B, Kitic D, Kostic S, Cvetkovic T, Djordjevic V. Acute renal failure after licorice ingestion: a case report. Cent Eur J Med. 2010;6(1):113-116.

17. Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26(3):377-384.

18. Lexicomp Online. Available at Last accessed April 30, 2021.

19. Tamargo J. New Drugs for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors: Hype or Hope? Available at Last accessed April 30, 2021.

20. Tamargo J, Caballero R, Delpon E. New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors. Cardiovasc Drugs Ther. 2018;32(1):99-119.

21. Hamdy O. Diabetic Ketoacidosis (DKA): Workup. Available at Last accessed April 30, 2021.

23. Frassetto LA, Lo LJ. Bartter Syndrome. Available at Last accessed April 30, 2021.

24. Dunn RL. Exposure to trimethoprim-sulfamethoxazole is associated with hospitalisation for hyperkalemia in older people with spironolactone. Evid Based Med. 2012;17(4):130-131.

25. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156-e166.

26. Diaz-Thomas A. Pseudohypoaldosteronism. Available at Last accessed April 30, 2021.

27. Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J. 2005;150(3):426-433.

28. Lainscak M, Pelliccia F, Rosano G, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone.Int J Cardiol. 2015;200:25-29.

29. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21(5):733-735.

30. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J. 2006;33(1):40-47.

31. U.S. Food and Drug Administration. FDA Approves New Drug to Treat Hyperkalemia. Available at Last accessed April 30, 2021.

32. Kovesdy CP. Management of hyperkalemia: an update for the internist. Am J Med. 2015;128(12):1281-1287.

33. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151-161.

34. Wie MR, Mayo MR, Garza D, et al. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. J Hypertens. 2017;(Suppl 1):S57-S63.

35. Montaperto AG, Gandhi MA, Gashlin LZ, Symoniak MR. Patiromer: a clinical review. Curr Med Res Opin. 2016;32(1):155-164.

36. Meaney CJ, Beccari MV, Yang Y, Zhao J. Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherpy. 2017;37(4):401-411.

37. Sarafidis PA, Georgianos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother. 2015;16(14):2205-2215.

38. Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6(6):CD013165.

39. Department of Health and Human Services. Food and Drug Administration. NDA Approval: Lokelma. Available at Last accessed April 30, 2021.

40. Highlights of prescribing Information: Lokelma. Available at Last accessed April 30, 2021.

41. Brown T. FDA Approves Lokelma for Hyperkalemia. Available at Last accessed April 30, 2021.

42. Hollander-Rodriguez JC, Calvert JF. Hyperkalemia. Am Fam Physician. 2006;73(2):283-290.

43. Family Practice Notebook. Hyperkalemia Management. Available at Last accessed April 30, 2021.

44. Griffing GT, Nagelberg SB, Odeke S. Addison Disease. Available at Last accessed April 30, 2021.

45. National Institute of Diabetes and Digestive and Kidney Diseases. Renal Tubular Acidosis. Available at Last accessed April 30, 2021.

46. Rodríguez Soriano J. Renal tubular acidosis: the clinical entity. JASN. 2002;13(8):2160-2170.

47. Chrousos GP, Sertedaki A, Kyritsi EM. Hyperaldosteronism. Available at Last accessed April 30, 2021.

Evidence-Based Practice Recommendations Citations

1. Management of Chronic Kidney Disease Working Group. VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease. Washington, DC: Department of Veterans Affairs, Department of Defense; 2019. Available at Last accessed May 17, 2021.

Copyright © 2021 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.